Table 3.
Length of antifungal therapy and outcome in never and ever smoker asthmatic subjects with airway mycosis
| Never smoker | Ever smoker | |||
|---|---|---|---|---|
| Antifungal | Number of cases | Length therapy mean wks (range) | Number of cases | Length therapy mean wks (range) |
| Voriconazole (N) | (14) | (9) | ||
| Positive response a (%) | 11 (78.6) | 14 (6‐28) | 9 (100) | 11 (4‐26) |
| No response b (%) | 3 (21.4) | 11 (6‐12) | 0 (0.0) | N/A |
| Fluc/Itra/Posa c (N) | (11) | (2) | ||
| Positive response (%) | 7 (63.6) | 14 (4‐12) | 1 (50.0) | 17 (17) |
| No response (%) | 4 (36.4) | 12 (12) | 1 (50.0) | 12(12) |
| Terbinafine (N) | (16) | (7) | ||
| Positive response (%) | 9 (56.3) | 9 (6‐12) | 5 (71.4) | 8 (6‐12) |
| No response (%) | 7 (43.8) | 7 (6‐12) | 2 (28.6) | 13 (6‐12) |
a
Patient improvement in any one or combination of the following variables: Decreased cough, improved breathing, decreased sputum, decreased wheezing, decreased rescue inhaler use, decreased controller use, decreased systemic steroid use.
b
No significant improvement in any of the clinically relevant responses describe in(a).
c
Fluc: fluconazole; Itra: itraconazole; Posa: posaconazole.